

Antibody engineering. December, 10-14, 2006. San Diego, CA





# Selection of a macaque scFv with human-like framework regions, nanomolar affinity, and that neutralizes the lethal factor (LF) of *Bacillus anthracis in vitro* and *in vivo*, by inhibiting the PA/LF complex formation.

An anti-LF (B. anthracis) neutralizing macaque scFv

 Thibaut Pelat<sup>1</sup>, Michael Hust<sup>2</sup>, Emmanuelle Laffly<sup>1</sup>, Florence Condemine<sup>1</sup>, Chantal Bottex<sup>1</sup>, Dominique Vidal<sup>1</sup>, Marie-Paule Lefranc<sup>3</sup>, Stefan Dübel<sup>2</sup>, <u>Philippe Thullier<sup>1</sup></u>

 1: Département de biologie des agents transmissibles, Centre de Recherche du Service de Santé des Armées, La Tronche, France (phullier@yahoo.com)

Separatement de oblige de agents duminisations, Centre de Ostante de Stattiere de Stattiere, La France, Parliere (France, Parliere)
 2 : Technische Universitä Braunschweig, Germany
 3 : Laboratoire d'ImmunoGénétique Moléculaire, LIGM, Université Montpellier II, UPR CNRS 1142, Institut de Génétique Humaine, IGH, Montpellier, France, and Institut Universitaire de France, Parlis, France.

#### **ABSTRACT :**

Toxins necessary for Bacillus anthracis pathogenesis are made of three sub-units : PA (protective antigen), LF (lethal factor) and EF (edema factor). Anti-PA recombinant antibodies have been developed for anthrax treatment, but other sub-units have not been targeted despite anthrax experts recommendations. Here, we describe an anti-LF scFv that was obtained from a macaque (Macaca fascicularis) immune antibody gene library ( $1.8x10^8$  clones) in pHAL14 phagemid vector. One scFv clone (2LF) selected from the library, had a high-affinity (KD = 1.02 nM), was highly neutralizing in the standardized in vitro (IC50 =  $1.17 \pm 0.06 \text{ nM}$ ) and in an in vivo assays. The genes encoding 2LF are similar to human immunoglobulin germline genes, and assigned to subgroups of human V, (D) or J genes by IMGT/V-QUEST. 2LF framework regions have a 84% identity with their most similar, germinally encoded human counterparts. This scFv neutralizes the anthrax lethal toxin by inhibiting the formation of the LF-PA complex, as shown in a competition assay. This inhibition suggests that 2LF interacts with domain 1 of LF, which is partially shared with EF and 2LF also reacted with EF, in ELISA and SPR. A 2LF-derived IgG, targeting LF and maybe EF, would be suitable for medical use.

#### MATERIAL AND METHODS : Immunization of a macaque (M. fascicularis) with LF, construction and successful screening of the library.



Screening of the library was performed by phage display technology and then 10, 20 and 40 washes were realized for each successive round of panning (see Laffly et al, Antimicrob Agents Chemother 49:3414-20; 2005.). A 15-fold increase in the number of cluted phages between the first and the last previous round, and a 4-fold increase in the phage-ELISA signal obtained with those phages indicated an enrichment in phages reacting specifically with LF.

## **RESULTS :** Selection of a scFv (2LF) reacting with LF (and EF), and neutralizing the anthrax lethal toxin



#### Mechanism for lethal toxin inhibition : competition between 2LF and PA for LF binding



## **PERSPECTIVES :**

The strategy proposed here is the targeting of a bacterial toxin implied in immune evasion of a bacterial pathogen. This is a major role of the bacterial proteins broadly designated as virulence factors, and targeting virulence factors could be of wide interest. For instance, in animal models, the targeting by murine monoclonals of F1 and LcrV, two major *Yersinia pestis* virulence factors, has proved to be protective. Beyond bioweapons, targeting virulence factors of bacteria that pose a threat to public health could be envisioned and macaque antibody fragments may also be enlisted in such more civilian combats.